| Document |
Document Title |
|
WO/2020/263768A1 |
Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.
|
|
WO/2020/262184A1 |
Provided is a novel method for inhibiting myostatin. An antisense oligonucleotide having a base length of 15-30 that has a base sequence complementary to the target site of exon 1 of myostatin gene, a salt thereof or a solvate of the s...
|
|
WO/2020/262591A1 |
The present invention addresses the problem of providing a muscle fatigue recovery promoting agent that can effectively promote recovery from muscle fatigue, and a method for producing a muscle fatigue recovery-promoting liquid comprisin...
|
|
WO/2020/262114A1 |
The purpose of the present invention is to provide a pharmaceutical agent which activates mitochondrial function, particularly, an inexpensive pharmaceutical agent. The problem can be solved by a mitochondrial function activator of the...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/254559A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/254690A1 |
The present invention relates to a method for modulating the effect of a botulinum neurotoxin composition, that is accelerating the onset of action and /or extending the duration of action and/or enhancing the intensity of action of a bo...
|
|
WO/2020/256397A1 |
The present invention relates to a composition for preventing or treating muscular diseases. More specifically, provided are a pharmaceutical composition and a health functional food composition for preventing or treating muscular diseas...
|
|
WO/2020/254553A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit ...
|
|
WO/2020/254664A1 |
A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acid...
|
|
WO/2020/255983A1 |
The present invention addresses the problem of providing a novel compound which exhibits a strong mPTP-opening inhibitory activity and/or a useful therapeutic effect against various diseases. One embodiment of the present invention perta...
|
|
WO/2020/257489A1 |
Methods for treating muscular dystrophy by administering a pharmaceutical composition comprising about 80 to about 300 mg/kg of an antisense oligomer, or pharmaceutically acceptable salt thereof, are described. In one embodiment, the com...
|
|
WO/2020/252146A1 |
The present disclosure provides compositions and methods based on the identification of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a therapeutic target in aging, dystrophic muscle to improve muscle atrophy, increase muscle mass, ...
|
|
WO/2020/249577A1 |
The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2
- b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be...
|
|
WO/2020/249717A1 |
The present invention relates to casein kinase 1 inhibitors alone or in combination with p38 inhibitors for use in the treatment of diseases related to DUX4 expression, such as muscular dystrophies and cancer.
|
|
WO/2020/252005A1 |
Disclosed herein are methods and compositions comprising alpha ketoglutarate (AKG) for altering senescence-associated secretory phenotype (SASP), and related diseases.
|
|
WO/2020/251020A1 |
The present invention addresses the problem of providing a cell population including mesenchymal cells, capable of forming a cell sheet that can be spontaneously peeled off from a substrate. The present invention relates to a cell popula...
|
|
WO/2020/251163A1 |
The present invention relates to a mutant non-toxic protease in which cysteine (Cys), the 430th amino acid of the non-toxic protease represented by an amino acid sequence of SEQ ID NO: 1, is substituted with an amino acid other than cyst...
|
|
WO/2020/247438A1 |
The present invention is directed to a method of replacing collagen broken down during physical activity using a novel dietary supplement. The supplement composition of the present invention comprises collagen, glutamine, taurine, and, o...
|
|
WO/2020/246564A1 |
The present invention addresses the problem of providing a method for predicting the therapeutic results of ATP augmentation treatment, and providing a method for distinguishing responders and non-responders in ATP augmentation treatment...
|
|
WO/2020/245191A1 |
The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of skeletal muscle disease and/or conditions. In one embodiment of the invention, said c...
|
|
WO/2020/246863A1 |
The present invention relates to a composition for preventing and treating muscular diseases, or improving muscle functions, which comprises Cudrania tricuspidate, such as a ground product or an extract thereof, as an effective component...
|
|
WO/2020/247607A1 |
The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Medi...
|
|
WO/2020/246430A1 |
Provided are a walking ability improver for improving walking ability, and a health-related QOL improver for improving mental health. This walking ability improver includes a component derived from lactic acid bacteria which are Lactobac...
|
|
WO/2020/244454A1 |
Disclosed are the medical use of a pentacyclic triterpenoid saponin compound and a pharmaceutical composition thereof, and in particular the use of the pentacyclic triterpenoid saponin compounds as shown in formulae (I) to (XVI) in the p...
|
|
WO/2020/245299A1 |
A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acid...
|
|
WO/2020/241638A1 |
Compounds represented by formula (I) below and pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and us...
|
|
WO/2020/237749A1 |
Provided is a compound having a long-acting therapeutic effect. The compound can be used to prepare an antidepressant drug and drugs for anesthesia, analgesia, improvement of cognitive function, lung protection, amyotrophic lateral scler...
|
|
WO/2020/241903A1 |
Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targetin...
|
|
WO/2020/238917A1 |
The present invention relates to a tetrahydro-1H-benzazepine compound as potassium channel modulator, a preparation method and a use thereof. Specifically, the compound of the present invention has the structure shown by formula A, where...
|
|
WO/2020/238763A1 |
Provided are an siRNA for inhibiting the expression of complement protein 5 (C5) gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide...
|
|
WO/2020/233522A1 |
The present invention relates to a method for preparing high-purity sugammadex sodium, same being prepared using phosphoinositide and a derivative thereof, the specific process being: adding a specific type of protective agent to crude s...
|
|
WO/2020/235582A1 |
The purpose of the present invention is to provide: a novel preventive and/or therapeutic agent for a motor neuron disease; and a pharmaceutical composition containing said preventive and/or therapeutic agent. The present invention inc...
|
|
WO/2020/234499A1 |
The present invention relates to a composition comprising citrulline malate, caffeine, L-glutamine, taurine, L-arginine and L-leucine, which can be a pharmaceutical or nutritional composition and is used mainly for muscular recovery and ...
|
|
WO/2020/234423A1 |
The presented invention relates to salts of Siponimod with Fumaric acid (1:1) and solid Forms 1 and 2 thereof. The presented invention further relates to salts of Siponimod with Maleic acid (1:1) and solid Forms 1, 2, 3, 4, 5, 6, 7, 8 an...
|
|
WO/2020/231989A1 |
Methods, compositions and kits for treating autophagy mediated diseases and disorders are disclosed as well as methods of treating a subject suffering from chronic granulomatous disease (CGD) by administering an effective amount of a thy...
|
|
WO/2020/230108A1 |
The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of ischemic stroke comprising administering an aptamer of the present disclosure to a subject in need thereof, alo...
|
|
WO/2020/230109A1 |
The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of a TLR-4 mediated disease or condition comprising administering an aptamer of the present disclosure to a subjec...
|
|
WO/2020/229539A1 |
A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle c...
|
|
WO/2020/232271A1 |
The present invention provides for methods and compositions for specifically targeting a nuclei type in a multinucleated cell or population of multinucleated cells, wherein the composition comprises one or more nucleotide sequences opera...
|
|
WO/2020/225606A1 |
The present disclosure provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD), e.g., through ex vivo and in vivo methods of genome editing. The present disclosure also relates to methods and composit...
|
|
WO/2020/223762A1 |
A method of modifying muscle or limb performance in a subject with or at risk of a condition associated with muscle atrophy, muscle fatty tissue, or pseudohypertrophy or a muscular dystrophy, by administering a pharmaceutical composition...
|
|
WO/2020/221780A1 |
The present invention concerns a composition comprising at least one creatine fatty ester or salt thereof, at least one omega 3 fatty acid or salt thereof and at least one glyceride for use in medicine, said composition being free of non...
|
|
WO/2020/222714A1 |
The present invention relates to pharmaceutical combinations comprising tolperisone or a pharmaceutically acceptable salt thereof and nimesulide or a pharmaceutically acceptable salt thereof in a single dosage form.
|
|
WO/2020/223097A1 |
Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic composi...
|
|
WO/2020/223092A1 |
Provided are topical analgesic spray compositions and topical analgesic spray concentrates containing menthol and camphor in high concentrations. The present disclosure also provides organoleptic compositions for use in the topical analg...
|
|
WO/2020/222566A1 |
The present invention relates to a pharmaceutical composition for preventing or treating myositis and, more specifically, to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredien...
|
|
WO/2020/223093A1 |
Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol an...
|
|
WO/2019/103109A9 |
The present invention provides a prophylactic and/or therapeutic agent for ALS that comprises an Src/c-Abl pathway inhibitor.
|
|
WO/2020/218720A1 |
The present invention relates to a novel use of Leonurus japonicus extract and leonurine used for preventing or treating muscular disorders or improving muscular functions, and relates to a composition for preventing or treating muscular...
|
